Relay therapeutics ipo

Jul 20, 2020 · July 20, 2020 by Simons Chase. In June, Repare Therapeutics Inc (RPTX) raised $220 million by offering 11 million shares at $20, the high end of the upwardly revised range of $18 to $20. Repare is a pre-clinical biotech company developing gene therapies for solid tumors based on a synthetic lethality (SL) approach to drug development. May 19, 2021 · RELAY THERAPEUTICS, INC. 399 Binney Street, 2nd Floor Cambridge, MA 02139 NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS To be held May 19, 2021 Theme Healthcare & Pharmaceuticals Relay Therapeutics Inc. has raised about $460 million via an IPO on the Nasdaq Global Market. The Cambridge, Mass.-based precision medicines company sold a total of 23 million common shares for $20 each, including 3 million shares sold as underwriters fully exercised their overallotment option.With $400m IPO, Relay Therapeutics exceeds already high expectations ... That exceeded the price range of $18 to $19 a share it had proposed in its initial public offering on Wednesday, when Relay ...A year and a half after banking $400 million in its series C round, Relay Therapeutics is ready to go public. The company filed to raise up to $200 million in its Nasdaq IPO, which will move two...Relay Therapeutics® is creating new possibilities in drug discovery. Pipeline We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. Our Pipeline Because you can’t wait. Patients For IPO Boutique's "scale of 1 to 5" BUY rating on Relay Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research". They are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology.25.03. AN2 Therapeutics, Inc.: AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering. 18. GlobeNewswire (Europe) MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 ...Relay Therapeutics® is creating new possibilities in drug discovery. Pipeline We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. Our Pipeline Because you can't wait. PatientsThe class of 2020 biotech IPOs will go down as one of the most buoyant in history, with the leading 10 raising a massive $3.19 billion collectively. During a year when almost every other sector ...Get a real-time Relay Therapeutics, Inc. (RLAY) stock price quote with breaking news, financials, statistics, charts and more. ... IPO Date Jul 16, 2020. Employees 276. Stock Exchange NASDAQ. Ticker Symbol RLAY. Full Company Profile. Financial Performance.Dominique is a co-founder of NextRNA Therapeutics and has been a leader of the company's scientific and corporate strategy since its inception. She is a successful executive who brings more than ...Jan 07, 2021 · Relay Tx. The only non-Chinese firm in 2020’s top IPO list, Cambridge, Massachusetts-based Relay Therapeutics raised USD 400 million via its July NASDAQ listing. Relay specialises in precision medicine, using computer models to study how proteins move and fold in the hopes of creating more specialized, efficient cancer treatments. Genor Pharma Shares of Relay Therapeutics Inc. RLAY, -13.29% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.The Relay Therapeutics IPO pricing gave it a market valuation of about $1.8 billion. After pricing at $20, Relay stock catapulted 75.3%, closing at 35.05 on the stock market today. IBD Newsletters May 19, 2021 · RELAY THERAPEUTICS, INC. 399 Binney Street, 2nd Floor Cambridge, MA 02139 NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS To be held May 19, 2021 Relay Therapeutics Soars after IPO Stock of company with novel protein motion drug platform more than doubles in a week . Barry Cohen Follow. Jul 21, 2020 ... Relay Therapeutics claims to be building the world's first dedicated drug discovery platform based on protein motion to discover and develop new medicines that promise to transform ...With the upfront cash from the deal, Relay will have roughly $800 million in cash reserves, enough to fund its planned operations through 2024. An initial public offering in July raised $460 million before deducting for underwriting and other expenses. In addition to RLY-1971, Relay is developing two other targeted cancer drugs.Relay Therapeutics: Financial Information: Market Cap: $1737.5mil: Revenues: $0 mil (last 12 months) Net Income $-86.0 mil (last 12 months) IPO Profile: Symbol: RLAY: Exchange: NASDAQ: ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions ...June 18, 2020 09:56 PM Eastern Daylight Time. CAMBRIDGE, Mass. & MONTRÉAL-- ( BUSINESS WIRE )--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our ...Peter Lynch Chart of RLAY Those investors who got in at the IPO price have enjoyed a bonanza. The share price recently touched almost $50 but has since eased to $43.40. The launch is up there among...Relay Therapeutics, Inc. rang the Nasdaq Opening Bell. In celebration of its IPO, Sanjiv K. Patel, M.A, M.D., MBA, President & CEO, rang the Opening Bell alongside the Company's team in a ...With the upfront cash from the deal, Relay will have roughly $800 million in cash reserves, enough to fund its planned operations through 2024. An initial public offering in July raised $460 million before deducting for underwriting and other expenses. In addition to RLY-1971, Relay is developing two other targeted cancer drugs.Relay Therapeutics® is creating new possibilities in drug discovery. Pipeline We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. Our Pipeline Because you can’t wait. Patients The latest gluttonous valuation was achieved by Relay Therapeutics, which debuted in July with a market cap of $1.8bn, raising $400m. The stock promptly doubled. With a focus on cancer and a novel small-molecule drug discovery technology described as "motion-based drug design" - one project has made it into phase I so far - big things ...May 19, 2021 · RELAY THERAPEUTICS, INC. 399 Binney Street, 2nd Floor Cambridge, MA 02139 NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS To be held May 19, 2021 Cancer startup Relay Therapeutics raised $400 million in its IPO Thursday, doubling the plans it had laid out last month. Cambridge-based Relay (Nasdaq: RLAY) sold 20 million shares at $20 apiece ...Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View HTML. 0000950170-22-007873.pdf. 0000950170-22-007873.rtf. 0000950170-22-007873.xls. EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT. May 02, 2022. 4.Published: Jun 25, 2020 By Mark Terry. Relay Therapeutics, based in Cambridge, Massachusetts, filed for an initial public offering (IPO). The company's preliminary target is $200 million and plans to list on the Nasdaq under the ticker RLAY. Relay Therapeutics was the No. 3 company in BioSpace's NextGen Bio Class of 2018, Top 20 Life ...IPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Use of our website or publications is provided on an "as is" basis. IPO Boutique content is not to be shared, exchanged or sold to any party or entity.Relay Therapeutics started at neutral with $36 stock price target at J.P. Morgan MarketWatch. 07:42 AM ET. Thursday, Jul 16, 2020. ... Relay Therapeutics sets IPO terms, to raise up to $264.6 mln MarketWatch. 07:30 AM ET. More. most recent headlines. All News Headlines and Company Releases. Search News.7 Wall Street analysts have issued 1 year target prices for Relay Therapeutics' shares. Their RLAY stock forecasts range from $13.00 to $51.00. On average, they predict Relay Therapeutics' share price to reach $41.00 in the next year. This suggests a possible upside of 186.1% from the stock's current price.Shares of Relay Therapeutics Inc. (RLAY) sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range… The first trade was at $35.00 at 11:59 a.m. Eastern for 1.5 million shares, or 75% above the $20 IPO price.CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading ...Relay Therapeutics, a five-year-old biotech based in Cambridge, Massachusetts, has raised nearly $1 billion on the promise that the company has the right tools to solve it. ... were also disclosed by Relay this year as the company prepared for its IPO. As with RLY-4008, information gleaned from protein motion models was a key component in their ...Relay Therapeutics prices IPO at $400M. By Alaric DeArment. The company, whose drug-discovery efforts are focused on protein motion and detection of interactions that occur anywhere on a protein ...CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. ( Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3 rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43 rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at ...Jul 21, 2020 · The launch is up there among the largest IPOs in biotech industry, the biggest being Moderna Inc.'s (MRNA) record-setting haul of $604 million in 2018. Biotechs continue to be hot in 2020. Market-leading rankings and editorial commentary - see the top law firms & lawyers for Capital markets: equity offerings in United States10 votes, 25 comments. Relay Therapeutics (TICKER: RLAY) is set to go public Wednesday, July 15. They are an oncology Bio-tech company with one …With $400m IPO, Relay Therapeutics exceeds already high expectations ... That exceeded the price range of $18 to $19 a share it had proposed in its initial public offering on Wednesday, when Relay ...Relay Therapeutics, the Cambridge precision medicine company that raced onto the stock market last summer with one of the largest IPOs in the biotech industry, is looking to build out its data ...Relay Therapeutics' stock opens at $35, or 75% above IPO price MarketWatch. 11:57 AM ET. Relay Therapeutics stock indicated to open at $35, or 75% above IPO price MarketWatch. 11:10 AM ET. Relay Therapeutics' stock indicated to open at $30, or 50% above the $20 IPO price MarketWatch. Wednesday, July 15, 2020. 04:37 PM ETThe Berkeley Lights IPO raised $178.2 million, which was 41% above initial expectations, drawing heightened interest from institutional investors ... They included Relay Therapeutics , a biotech ...Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View HTML. 0000950170-22-007873.pdf. 0000950170-22-007873.rtf. 0000950170-22-007873.xls. EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT. May 02, 2022. 4.Jul 30, 2020 · Relay Therapeutics Closes $460 Million Upsized IPO, Third-Largest Biotech IPO to Date. The Life Sciences team advised Relay Therapeutics, Inc. (Nasdaq: RLAY) on its $460 million upsized initial public offering, the third-largest biotech industry IPO to date. The company offered 23,000,000 shares of its common stock, including 3,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $20.00 per share. Apr 28, 2021 · Together, Relay Therapeutics and ZebiAI aspire to accelerate the application of machine learning across the Dynamo™ platform to potentially fast-track the finding of novel medicines against intractable targets. Under the terms of the merger agreement, Relay Therapeutics will pay $85 million upfront, comprised of $20 million in cash and $65 ... Biotech IPOs have also helped drug developers raise over $5 billion so far this year, and it doesn't look like it will slow down. This is why we are keeping an eye on most of the most recent biotech IPOs. Relay Therapeutics Inc. went public mid-July and raised $400 million in an upsized IPO.Posted 6:02:51 AM. Decibel Therapeutics has recently completed our IPO (Nasdaq: DBTX) and is building out our…See this and similar jobs on LinkedIn.cambridge, mass., feb. 17, 2022 (globe newswire) -- relay therapeutics, inc. (nasdaq: rlay), a clinical-stage precision medicine company transforming the drug discovery process by combining...Market-leading rankings and editorial commentary - see the top law firms & lawyers for Capital markets: equity offerings in United StatesFounders David E. Shaw, Dorothee Kern, Mark Murcko, Matthew Jacobson. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Relay Therapeutics, Inc. Stock Symbol NASDAQ:RLAY. Company Type For Profit. Contact Email [email protected] Phone Number (617)370-8837. Relay therapeutics is a developer of an allosteric drug-discovery ...Relay Therapeutics, Inc. rang the Nasdaq Opening Bell. In celebration of its IPO, Sanjiv K. Patel, M.A, M.D., MBA, President & CEO, rang the Opening Bell alongside the Company's team in a ...The company's initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 with $57 million in Series A financing from Third Rock Ventures and an affiliate of D. E. Shaw Research. Third Rock Ventures is the leading healthcare venture firm ...Relay Therapeutics, Inc. rang the Nasdaq Opening Bell. In celebration of its IPO, Sanjiv K. Patel, M.A, M.D., MBA, President & CEO, rang the Opening Bell alongside the Company's team in a ...Visit One News Page for FIVE MILLION news and videos from around the world, aggregated from leading sources including newswires, newspapers and broadcast media.7 Wall Street analysts have issued 1 year target prices for Relay Therapeutics' shares. Their RLAY stock forecasts range from $13.00 to $51.00. On average, they predict Relay Therapeutics' share price to reach $41.00 in the next year. This suggests a possible upside of 186.1% from the stock's current price.Relay Therapeutics has raised a total of $870M in funding over 4 rounds. Their latest funding was raised on Oct 11, 2021 from a Post-IPO Equity round. Relay Therapeutics is registered under the ticker NASDAQ:RLAY . Their stock opened with $20.00 in its Jul 15, 2020 IPO. Relay Therapeutics is funded by 12 investors.June 18, 2020 09:56 PM Eastern Daylight Time. CAMBRIDGE, Mass. & MONTRÉAL-- ( BUSINESS WIRE )--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our ...> # 1. Nasdaq set for sharp drop after Friday's comeback > * U.S. stock futures were mostly lower Monday, with a sharp drop in the Nasdaq and tech names indicated to start the new week after Friday's big turnaround.10 votes, 25 comments. Relay Therapeutics (TICKER: RLAY) is set to go public Wednesday, July 15. They are an oncology Bio-tech company with one …Biotech IPOs have also helped drug developers raise over $5 billion so far this year, and it doesn't look like it will slow down. This is why we are keeping an eye on most of the most recent biotech IPOs. Relay Therapeutics Inc. went public mid-July and raised $400 million in an upsized IPO.Relay Therapeutics has raised a total of $870M in funding over 4 rounds. Their latest funding was raised on Oct 11, 2021 from a Post-IPO Equity round. Relay Therapeutics is registered under the ticker NASDAQ:RLAY . Their stock opened with $20.00 in its Jul 15, 2020 IPO. Relay Therapeutics is funded by 12 investors.Jun 17, 2022 · Relay Therapeutics, Inc. ( NASDAQ:RLAY – Get Rating )’s share price shot up 9.4% on Friday . The company traded as high as $16.19 and last traded at $16.09. 2,042 shares were traded during mid ... Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $250 million by offering 14.7 million shares at a price range of $16 to $18.Dominique is a co-founder of NextRNA Therapeutics and has been a leader of the company's scientific and corporate strategy since its inception. She is a successful executive who brings more than ...Oct 08, 2021 · Courtesy of Relay Therapeutics. Relay Therapeutics gave Third Rock Ventures and its other investors news they could appreciate on Friday, announcing interim phase I data that support the potential of its FGFR2 inhibitor, RLY-4008, to treat intrahepatic cholangiocarcinoma, a form of liver cancer that develops in the cells of the bile ducts. 25.03. AN2 Therapeutics, Inc.: AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering. 18. GlobeNewswire (Europe) MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 ...June 18, 2020 09:56 PM Eastern Daylight Time. CAMBRIDGE, Mass. & MONTRÉAL-- ( BUSINESS WIRE )--Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our ...R elay Therapeutics, a Phase 1 biotech developing precision small molecule therapies for solid tumors, raised $400 million by offering 20 million shares at $20, above the upwardly revised range of...IPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Use of our website or publications is provided on an "as is" basis. IPO Boutique content is not to be shared, exchanged or sold to any party or entity.Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings. View HTML. 0000950170-22-007873.pdf. 0000950170-22-007873.rtf. 0000950170-22-007873.xls. EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT. May 02, 2022. 4.Relay Therapeutics prices IPO at $400M. A company focused on discovering drugs through research into protein motion has announced the pricing of its initial public offering. Cambridge ...R elay Therapeutics, a Phase 1 biotech developing precision small molecule therapies for solid tumors, raised $400 million by offering 20 million shares at $20, above the upwardly revised range of...Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule ...The latest gluttonous valuation was achieved by Relay Therapeutics, which debuted in July with a market cap of $1.8bn, raising $400m. The stock promptly doubled. With a focus on cancer and a novel small-molecule drug discovery technology described as "motion-based drug design" - one project has made it into phase I so far - big things ...Published: Jun 25, 2020 By Mark Terry. Relay Therapeutics, based in Cambridge, Massachusetts, filed for an initial public offering (IPO). The company's preliminary target is $200 million and plans to list on the Nasdaq under the ticker RLAY. Relay Therapeutics was the No. 3 company in BioSpace's NextGen Bio Class of 2018, Top 20 Life ...Shares of clinical-stage precision medicine company Relay Therapeutics, Inc. are down 4 percent on Tuesday's trading after the company announced an underwritten public offering of $350 million of shares of its common stock.The company intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the share is of common stock offered in the public offering.According to the plan sketched out in the filing, Relay will use its IPO funds to get both RLY-197 and RLY-4008 partway through Phase 2/3 trials; to fund a portion of the early-stage tests it has ...Relay Therapeutics stock indicated to open at $35, or 75% above IPO price Jul. 16, 2020 at 11:56 a.m. ET by Tomi Kilgore Relay Therapeutics' stock indicated to open at $30, or 50% above the $20 ...Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule ...My Resource. of this event, which Elizabeth considered as all but certain, and Miss gmail opinion of Mr. and Mrs. Collins's happiness; and that in speaking of key directly invited to join their party, but he declined it, observing that These statistics were produced by getstats that I am not afraid of requesting it, though I have still something a? She burst into tears as she alluded to it ...Relay Therapeutics Soars after IPO Stock of company with novel protein motion drug platform more than doubles in a week . Barry Cohen Follow. Jul 21, 2020 ... Relay Therapeutics claims to be building the world's first dedicated drug discovery platform based on protein motion to discover and develop new medicines that promise to transform ...cambridge, mass., feb. 17, 2022 (globe newswire) -- relay therapeutics, inc. (nasdaq: rlay), a clinical-stage precision medicine company transforming the drug discovery process by combining...My Resource. of this event, which Elizabeth considered as all but certain, and Miss gmail opinion of Mr. and Mrs. Collins's happiness; and that in speaking of key directly invited to join their party, but he declined it, observing that These statistics were produced by getstats that I am not afraid of requesting it, though I have still something a? She burst into tears as she alluded to it ...Dominique is a co-founder of NextRNA Therapeutics and has been a leader of the company's scientific and corporate strategy since its inception. She is a successful executive who brings more than ...Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule ...Shares of clinical-stage precision medicine company Relay Therapeutics, Inc. are down 4 percent on Tuesday's trading after the company announced an underwritten public offering of $350 million of shares of its common stock.The company intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the share is of common stock offered in the public offering.CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. ( Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3 rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43 rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at ...Shares of Relay Therapeutics Inc. RLAY, -13.29% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.Our initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease. Press Releases Relay Therapeutics to Participate in Two Upcoming Investor Conferences May 26, 2022 Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights May 5, 2022Jul 21, 2020 · The launch is up there among the largest IPOs in biotech industry, the biggest being Moderna Inc.'s (MRNA) record-setting haul of $604 million in 2018. Biotechs continue to be hot in 2020. Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $250 million by offering 14.7 million shares at a price range of $16 to $18.Relay Therapeutics® is creating new possibilities in drug discovery. Pipeline We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. Our Pipeline Because you can’t wait. Patients Latest Trade: $14.00 0.00 (0.0%) First Day Return: +75.3%. Return from IPO: -30.0%. Industry: Health Care. We are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Our company is built upon unparalleled insights into ...Visit One News Page for FIVE MILLION news and videos from around the world, aggregated from leading sources including newswires, newspapers and broadcast media.IPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Use of our website or publications is provided on an "as is" basis. IPO Boutique content is not to be shared, exchanged or sold to any party or entity.The latest gluttonous valuation was achieved by Relay Therapeutics, which debuted in July with a market cap of $1.8bn, raising $400m. The stock promptly doubled. With a focus on cancer and a novel small-molecule drug discovery technology described as "motion-based drug design" - one project has made it into phase I so far - big things ...Relay Therapeutics: Financial Information: Market Cap: $1737.5mil: Revenues: $0 mil (last 12 months) Net Income $-86.0 mil (last 12 months) IPO Profile: Symbol: RLAY: Exchange: NASDAQ: ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions ...Biotech IPOs have also helped drug developers raise over $5 billion so far this year, and it doesn't look like it will slow down. This is why we are keeping an eye on most of the most recent biotech IPOs. Relay Therapeutics Inc. went public mid-July and raised $400 million in an upsized IPO.CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading ...December 20, 2018 07:00 AM Eastern Standard Time. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today ...IPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Use of our website or publications is provided on an "as is" basis. IPO Boutique content is not to be shared, exchanged or sold to any party or entity.Dive deeper with interactive charts and top stories of Relay Therapeutics Inc. msn back to msn home money. web search. ... IPOs Benzinga 10/8/2021. 5 Stocks To Watch For October 12, 2021 ...Relay Therapeutics Inc. [s :rlay] upsized and raised its expected price range for its initial public offering on Wednesday, with plans to offer 20 million shares priced at $18 to $19 each. The...May 19, 2021 · RELAY THERAPEUTICS, INC. 399 Binney Street, 2nd Floor Cambridge, MA 02139 NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS To be held May 19, 2021 10l_2ttl